Fintel reports that on September 19, 2024, B. Riley Securities initiated coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (NasdaqGS:CNTA) with a Buy recommendation.
Analyst Price Forecast Suggests 6.69% Downside
As of August 25, 2024, the average one-year price target for Centessa Pharmaceuticals plc - Depositary Receipt () is $14.79/share. The forecasts range from a low of $11.11 to a high of $21.00. The average price target represents a decrease of 6.69% from its latest reported closing price of $15.85 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Centessa Pharmaceuticals plc - Depositary Receipt () is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -2.15.
What is the Fund Sentiment?
There are 105 funds or institutions reporting positions in Centessa Pharmaceuticals plc - Depositary Receipt (). This is an increase of 14 owner(s) or 15.38% in the last quarter. Average portfolio weight of all funds dedicated to CNTA is 1.13%, an increase of 5.92%. Total shares owned by institutions increased in the last three months by 25.11% to 87,124K shares. 
The put/call ratio of CNTA is 0.11, indicating a bullish outlook.
What are Other Shareholders Doing?
Medicxi Ventures Management holds 19,963K shares. No change in the last quarter.
General Atlantic holds 9,682K shares. No change in the last quarter.
EcoR1 Capital holds 5,714K shares. In its prior filing, the firm reported owning 5,619K shares , representing an increase of 1.67%. The firm decreased its portfolio allocation in CNTA by 1.70% over the last quarter.
First Light Asset Management holds 4,781K shares. In its prior filing, the firm reported owning 3,002K shares , representing an increase of 37.20%. The firm increased its portfolio allocation in CNTA by 45.70% over the last quarter.
Perceptive Advisors holds 3,933K shares. In its prior filing, the firm reported owning 3,083K shares , representing an increase of 21.61%. The firm increased its portfolio allocation in CNTA by 40.34% over the last quarter.
Centessa Pharmaceuticals Background Information
(This description is provided by the company.)
Centessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa wholly owns ten of these asset-centric companies. The companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Centessa’s asset-centric companies are overseen by the Centessa management team, which sets overall strategy and direction, provides leadership and expertise, and manages resource allocation and shared infrastructure.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
